A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma (NHL)
There are 2 phases in this study: Stage 1 (dose escalation) and Stage 2 (dose expansion). The goal of Stage 1 of this clinical research study is to find the highest tolerable dose of IGN002 that can be given to patients with refractory NHL. The goal of Stage 2 of this clinical research study is to learn if the highest tolerated dose in Stage 1 can help to control the disease. The safety of this drug will be studied in both stages of the study. This is the first study using IGN002 in humans. IGN002 is a combination of Rituxan® (rituximab) and interferon-alpha.
Treatment Location: N/A
IRB Review and Approval Date: 05/18/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: